BiotechTube
Veradermics

Veradermics

MANE
New York, United States· Est.
veradermics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

MANE · Stock Price

USD 107.85+70.10 (+185.70%)
Market Cap: $4.6B

Historical price data

Market Cap: $4.6BPipeline: 5 drugs (3 Phase 3)Founded: 2021Employees: 11-50HQ: New York, United States

Overview

Veradermics is a late-stage biopharma company founded by practicing dermatologists to develop novel therapeutics for high-prevalence, under-innovated dermatologic conditions. Its core strategy leverages deep clinical expertise to reformulate proven compounds, de-risking development and focusing on real-world patient needs. The company's lead asset, VDPHL01 for pattern hair loss, is in Phase 3 trials, positioning it to potentially capture a multi-billion dollar market with a first-in-class oral therapy.

DermatologyAesthetics

Technology Platform

Proprietary extended-release formulation and drug delivery optimization applied to compounds with established biological activity, focusing on improving safety, efficacy, and convenience.

Pipeline

5
5 drugs in pipeline3 in Phase 3
DrugIndicationStageWatch
VDPHL01 QD + Placebo + VDPHL01 BID + PlaceboAndrogenetic Alopecia (AGA)Phase 3
VDPHL01 + PlaceboAndrogenetic AlopeciaPhase 3
VDPHL01 + PlaceboAndrogenetic AlopeciaPhase 2/3
VDPHL01Androgenetic AlopeciaPhase 2
VDMN-21 Patch Low Dose + VDMN-21 Patch High Dose + Vehicle P...Verruca VulgarisPhase 2

Funding History

3
Total raised:$135M
Venture$75M
Series A$50M
Seed$10M

Opportunities

VDPHL01 addresses a multi-billion dollar global market for pattern hair loss with no new prescription therapies in nearly 30 years, particularly for women who have no FDA-approved oral option.
Success could validate the company's platform for other high-prevalence, under-innovated dermatologic conditions.

Risk Factors

The company faces binary clinical risk in its Phase 3 trials for VDPHL01, regulatory uncertainty, and future commercial competition from low-cost generics and newer therapies.
As a pre-revenue company with a concentrated pipeline, it is also dependent on favorable capital markets for funding.

Competitive Landscape

VDPHL01 competes against topical minoxidil (poor adherence) and oral finasteride (hormonal side effects, not for women). It holds a late-stage advantage over novel-mechanism developmental drugs. Its key differentiation is a convenient oral formulation of a proven drug, designed for improved safety and efficacy.

Company Timeline

2021Founded

Founded in New York, United States

2022Series A

Series A: $50.0M

2024Venture

Venture: $75.0M

More companies in United States →